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Objectives: The goal of this study was to determine whether there are 
differences in populations of patients with heart failure who require univen- 
tricular or biventricular circulatory support. Methods: Two hundred thirteen 
patients who were in imminent risk of dying before donor heart procurement 
and who received Thoratec left (LVAD) and right (RVAD) ventricular assist 
devices at 35 hospitals were divided into three groups: group 1 (n = 74), 
patients adequately supported with isolated LVADs; group 2 (n = 37), patients 
initially receiving an LVAD and later requiring an RVAD; and group 3 (n = 
102), patients who received biventricular assistance (BiVAD) from the begin- 
ning. Results: There were no significant differences in any preoperative factors 
between the two BiVAD groups. In the combined BiVAD groups, pre-VAD 
cardiac index (BiVAD, 1.4 -- 0.6 L/min per square meter, vs LVAD, 1.6 + 0.6 
L/min per square meter) and pulmonary capillary wedge pressure (BiVAD, 
27 -+ 8 mm Hg, vs LVAD, 30 - 8 mm Hg) were significantly lower than those 
in the LVAD group, and pre-VAD creatinine levels were significantly higher 
(BiVAD, 1.9 -+ 1.1 mg/dl, vs LVAD, 1.4 -+ 0.6 mg/dl). In addition, greater 
proportions of patients in the BiVAD groups required mechanical ventilation 
before VAD placement (60% vs 35%) and were implanted under emergency 
conditions than in the LVAD group (22% vs 9%). The survival of patients 
through heart transplantation was significantly better in patients who had an 
LVAD (74%) than in those who had BiVADs (58%). However, there were no 
significant differences in posttransplantation survival through hospital dis- 
charge (LVAD, 89%; BiVAD, 81%). Conclusion: Patients who received LVADs 
were less severely ill before the operation and consequently were more likely to 
survive after the operation. As the severity of illness increases, patients are 
more likely to require biventricular support. (J Thorac Cardiovasc Surg 1997; 
113:202-9) 
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T he decision to use univentricular or biventricular support is one of the key problems in the suc- 
cessful application of mechanical circulatory sup- 
port for the treatment of patients with heart failure. 
With appropriate selection and exclusion criteria, 
many patients can be identified and supported suc- 
cessfully with an isolated left ventricular assist de- 
vice (LVAD). However, they represent only part of 
the total population of patients requiring mechani- 
cal circulatory support. Another sizable part of the 
population requires biventricular (BiVAD) support 
with both left (LVAD) and right (RVAD) ventric- 
ular assist devices; another group of patients, al- 
though rauch smaller in number, require isolated 
RVAD support. There is continued controversy 
over the percentage of patients requiring BiVAD 
support. These figures range from more than 60% in 
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Fig. 1. Schematic diagram showing Thoratec LVAD (A) and biventricular devices (LVAD and RVAD) 
(B). The LVAD is shown connected from the apex of the left ventricle and returning blood flow to the aorta 
(Ao). In some patients, left atrial cannulation is used instead of apical cannulation. The RVAD is 
connected from the right atrium (RA) returning blood flow to the pulmonary artery (PA). 
patients selected for treatment with Thoratec 
LVADs or RVADs, or both (Thoratec Laborato- 
ries, Berkeley, Calif.), >» to 15% to 25% in patient 
populations elected for isolated LVAD systems. 6-8 
These percentages reflect differences in the patient 
populations tudied, as well as selection bias among 
different investigators. However, there are no reli- 
able preoperative predictors of right heart failure 
with isolated LVAD support and no consensus on 
how to best select univentricular and biventricular 
devices for the total patient population requiring 
circulatory support. Accordingly, we tried to deter- 
mine whether there are differences in populations of 
patients who require biventricular versus univen- 
tricular support by performing a retrospective anal- 
ysis of the severity of illness and survival of patients 
receiving Thoratec LVADs  compared with patients 
receiving biventricular support (LVADs and 
RVADs). 
Methods 
Patient entry criteria. Patients in this study were heart 
transplant candidates in whom VADs were implanted 
when the clinical and hemodynamic status indicated that 
the patient would probably die or have permanent end- 
organ damage before a donor heart could be located. 
Hemodynamic guidelines used in the Investigational De- 
vice Exemption (IDE) study in the United States were (1) 
a left atrial pressure greater than 20 mm Hg and either (2) 
a cardiac index less than 1.8 L/min per square meter or (3) 
a mean arterial pressure less than 70 mm Hg, despite 
appropriate use of conventional therapies such as inotro- 
pic agents, vasodilators, and intraaortic balloon pumps. 
No patient was accepted for the study who had known 
contraindications to cardiac transplantation other than 
those considered to be reversible after restoration of 
adequate cardiac output. Once the patient met entry 
criteria, investigational sites were free to apply LVADs or 
RVADs (or both) as required for individual patient need. 
VAD. The Thoratec VAD system was used for either 
univentricular or biventricular support in these patients. 
The system consists of prosthetic ventricles with a 65 ml 
stroke volume, cannulas for atrial or ventricular inflow 
and arterial outflow connections, and a pneumatic drive 
console. The VADs were placed in a paracorporeal 
position on the anterior abdominal wall and were con- 
nected to the heart and great vessels with cannulas 
crossing the chest wall (Fig. 1). Surgical implantation 
procedures have been previously published, 9 and clinical 
experiences with the Thoratec VAD system are well 
described in the literature. 2-s' lo 
Patient population. Data available for analysis for this 
report were from 213 patients who received VADs for left 
ventricular (LV) or biventricular support at 35 medical 
centers in seven countries. This data set represents ap- 
proximately half of the known bridge-to-transplantation 
cases with the Thoratec VAD at the time of preparation 
of this manuscript. Corona£g artery disease had been 
diagnosed in 95 patients (end-stage ischemic heart disease 
in 79 patients and acute myocardial infarction in 16), 
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Table I. Initial and final configuration of 213 patients with LVAD and BiVAD support 
Initial configuration Groups in stu@ Final configuration 
~. , , . . , . .~Group 1, n = 74 (35%), LVAD LVAD, n = 74 (35%) 
LVAD, n = 111 ( 5 2 % ) ~  
~ G r o u p  2, n 37 (17%), converted to BiVAD* 
BiVAD, n = 149 (65%) 
BiVAD, n = 102 (48%) Group 3, n = 102 (48%), initial BiVAD 
Total = 213 
*Represents 33% (37/111) of those initially chosen for LVAD support. 
dilated cardiomyopathy in 90 patients (11 known viral, 11 
postpartum, and 68 idiopathic), and graft failure or rejec- 
tion after prior orthotopic ardiac transplantation in 13 
patients. An additional 15 patients (2 hypertrophic car- 
diomyopathy, 4 valvular disease, 4 myocarditis, 3 doxoru- 
bicin-induced cardiomyopathy, 1 transposition of the 
great arteries, and 1 unknown) received VADs. There 
were 164 male (77%) and 49 female patients (23%) with 
an average age of 43 years (range 11 to 63 years), an 
average body surface area of 1.88 m 2 (range 1.06 to 2.55 
m2), and an average weight of 75 kg (range 30 to 126 kg). 
Patients were divided into three groups: group 1 
(LVAD), patients who received isolated LVAD support, 
were supported adequately in this mode, and did not 
require the addition of an RVAD; group 2 (BiVAD 
converted from LVAD), patients who initially received an 
LVAD but subsequently had profound right heart failure 
refractory to pharmacologic therapy and required the 
additional use of an RVAD; and group 3 (BiVAD initial- 
ly), patients in whom biventricular devices (both LVADs 
and RVADs) were implanted from the beginning. 
Patient demographic nformation and clinical status 
were determined before VAD implantation. Blood chem- 
istry values for creatinine, blood urea nitrogen, aspartate 
aminotransaminase, and total bilirubin levels were mea- 
sured before the operation and throughout VAD support. 
Patient survival was determined at two stages: pretrans- 
plantation survival (the percentage of those receiving a 
VAD who survived to receive a heart transplant) and 
posttransplantation survival (through ospital discharge). 
Studies in the United States were conducted under 
investigational-device-exemption (IDE) regulations, with 
protocol and patient consent forms approved by the 
institutional review boards and by the U.S. Food and Drug 
Administration. Informed consent was obtained from 
either the patient or hext of kin. 
Statistical methods. Comparisons were made first be- 
tween the two BiVAD groups (groups 2 and 3), and if no 
significant differences were found, these two groups were 
combined. Differences between two groups of patients for 
continuous variables were assessed with a t test. Univari- 
ate tests of association were performed with Fisher's exact 
test for 2 × 2 comparisons or with a )(2 test for 2 × k 
comparisons. A p value of less than 0.05 was considered 
significant for all evaluations. All statistical analyses were 
performed with the use of the Crunch (Version 4; Oak- 
land, Calif.) statistical data package on a personal com- 
puter. 
Results 
Distribution of VADs. The distribution of pa- 
tients in the three groups is illustrated in Table I. Of 
the 213 total patients analyzed, 111 patients (52%) 
were initially supported with isolated LVADs, and 
102 patients (48%) were initially supported with 
LVADs and RVADs. Of the 111 patients initially 
receiving LVADs, a total of 37 (33%) had profound 
right heart failure after LVAD support was initi- 
ated, requiring additional support with an RVAD. 
Thus these 111 patients were divided into two 
groups: group 1 (LVAD) consists of the 74 patients 
having only LVADs and group 2 (BiVAD converted 
from LVAD) consists of the 37 patients requiring 
RVADs in addition to the LVAD. In the 37 patients 
in group 2, the RVAD was added in 13 patients after 
failure to wean from cardiopulmonary b pass with 
an isolated LVAD because of concomitant right 
ventricular (RV) failure, 18 were converted to 
BiVAD after termination of bypass demonstrated 
profound RV failure severe enough to warrant 
initiation of RV support, and in six patients the 
RVAD was added during a reoperation 4 to 19 
hours after the initial procedure to implant the 
LVAD. Of the 102 patients in group 3 (initial 
BiVAD), biventricular devices were used in 30 
patients requiring emergency VAD implantation 
(cardiopulmonary esuscitation in progress or pe- 
ripheral cardiopulmonary b pass required to stabi- 
lize the patient for transfer to the operating room 
for VAD implantation); BiVADs were also used in 
38 patients because of potential letha! arrhythmias 
and in 34 patients because of a preoperative clinical 
decision on biventricular failure. 
Pre-VAD patient status. A comparison between 
the LVAD and BiVAD groups showing statistically 
significant and nonsignificant factors is presented in 
Table II. There were no significant differences for 
any factor between the two BiVAD groups, which 
were subsequently combined. Comparisons were 
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Table II. Compar&on of variables measured pre-VAD between patients who received isolated LVAD and 
BiVAD support (mean +_ standard deviation) 
BiVAD 
Converted Initial All 
L VAD BiVAD BiVADs BiVADs 
Pre-VAD variable (n = 74) (n = 37) (n = 102) (n = 139) p Value* 
Statistically significant factors 
Cardiac index (L/min/m z) 1.6 _+ 0.6 1.5 _+ 0.7 1.3 +_ 0.8 1.4 _+ 0.8 0.024 
PCWP (mm Hg) 30 _+ 8 26 _+ 7 28 _+ 8 27 + 8 0.024 
Creatinine (mg/dl) 1.4 _+ 0.6 1.9 +- 0.9 1.9 -+ 1.2 1.9 _+ 1.1 0.002 
Total bilirubin (mg/dl) 1.5 _+ 0.9 2.0 _+ 1.9 2.1 + 2.1 2.1 _+ 2.1 0.05 
Emergency implant 9% 14% 25% 22% 0.030 
IABP 46% 65% 67% 66% 0.007 
Mechanical ventilation 35% 60% 61% 60% 0.001 
Statistically nonsignificant factors 
Etiology 
Coronary artery disease 54% 30% 43% 40% 
Dilated cardiomyopathy 37% 51% 45% 47% NS 
Other 9% 19% 12% 14% 
MAP (mm Hg) 65 + 12 66 +_ 18 63 _+ 13 64 _+ 14 NS 
RAP (mm Hg) 17 _+ 7 19 _+ 7 19 _+ 8 19 _+ 7 NS 
PAP (mm Hg) 39 -+ 10 38 -+ 14 37 +- 12 37 + 12 NS 
BUN (mg/dl) 32 _+ 18 35 + 16 36 _+ 20 36 _+ 19 NS 
AST (IU) 234 _+ 452 588 -+ 1333 613 + 2502 607 _+ 2290 NS 
Age (yr) 43 _+ 14 42 _+ 14 43 _+ 13 43 _+ 13 NS 
BSA (m 2) 1.89 -+ 0.24 1.84 -+ 0.22 1.89 _+ 0.22 1.88 _+ 0.22 NS 
Cardiac arrest 36% 32% 47% 43% NS 
For BiVAD support, the two subgroups are shown separately and combined. Percents hown are the percentages of the number of patients in the group. 
/ABP, Intraaortic balloon pump; MAP, PAP, RAP, mean arterial, mean pulmonary arterial, and right atrial pressures, respectively; BUN, blood urea nitrogen; 
AST, aspartate aminotransferase; BSA, body surface area; NS, not significant. 
*All BiVAD patients versus LVAD patients. 
then made for the combined BiVAD groups versus 
the LVAD group. Pre-VAD cardiac index was sig- 
nificantly less in the combined BiVAD groups than 
in the LVAD group (BiVAD 1.4 _+ 0.6 L/min per 
square meter; LVAD 1.6 _+ 0.6 L/min per square 
meter), and pulmonary capillary wedge pressure was 
less (BiVAD 27 + 8 mm Hg; LVAD 30 _+ 8 mm 
Hg). Pre-VAD creatinine levels were significantly 
higher (BiVAD 1.9 + 1.1 mg/dl; LVAD 1.4 _+ 0.6 
mg/dl), and pre-VAD total bilirubin levels were 
higher (BiVAD 2.1 + 2.1 mg/dl; LVAD 1.5 _+ 0.9 
mg/dl). In addition, more patients in the BiVAD 
groups than in the LVAD group required mechan- 
ical ventilation before VAD placement (60% vs 
35%), more received the implant under emergency 
conditions (cardiopulmonary resuscitation in 
progress or peripheral cardiopulmonary b pass re- 
quired to transport he patient to the operating 
room for VAD implantation) (22% vs 9%), and 
more had intraaortic balloon pump usage before the 
operation (66% vs 46%). 
The remainder of factors in Table II were not 
statistically different between the LVAD and BiVAD 
groups. Of interest, hough, is that a higher propor- 
tion of patients receiving an LVAD (54%) had 
coronary artery disease rather than dilated cardio- 
myopathy (37%), whereas a higher proportion of 
the BiVAD group appeared to have dilated cardio- 
myopathy (46%) rather than coronary artery disease 
(40%); this difference did not reach significance, 
however (p = 0.09 when comparing only patients 
with coronary artery disease and dilated cardiomy- 
opathy and p = 0.13 when including posttransplan- 
tation heart failure and the "other" etiologies). 
There were also no significant differences in pre- 
VAD right heart hemodynamic values between the 
LVAD and BiVAD groups; blood urea nitrogen, 
aspartate aminotransferase, age, body surface area, 
and the proportion of patients with pre-VAD car- 
diac arrests was also not significantly different be- 
tween LVAD and BiVAD groups. 
Factors during YAD support. Comparisons of 
the LVAD and BiVAD groups during VAD support 
are shown in Table III. Bleeding and renal failure 
were more frequent complications in patients re- 
ceiving biventricular support, as indicated by the 
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Table III. Comparison of variables measured during VAD support between patients who received isolated 
LVAD and BiVAD support 
BiVAD 
Converted Initial All 
Factor L VAD BiVAD BiVADs BiVADs p Value* 
Factors during VAD support 
Renal dialysis 5% 24% 20% 21% 0.003 
Reoperations for bleeding 14% 35% 32% 33% 0.002 
LV cannulation site 71% 57% 61% 60% NS 
LVAD flow index at 30 days (L/min/m:) 
LV cannulation 2.8 + 0.5 2.9 _+ 0.5 3.0 _+ 0.5 3.0 -+ 0.5 NS 
LA cannulation 2.5 + 0.4 2.5 _+ 0.4 2.5 _+ 0.4 2.5 -+ 0.4 NS 
Survival 
Implant-to-transplant 74% 62% 56% 58% 0.017 
Transplant-to-discharge 89% 83% 81% 81% NS 
For BiVAD support, the two subgroups are shown separately and combined. Percents hown are the percentages of the number of patients in the group. NS, 
Not significant; LA, left atrial. 
*All BiVAD patients versus LVAD patients. 
greater percentage of patients requiring renal dial- 
ysis and reoperations to control bleeding. However, 
creatinine, total bilirubin, and aspartate aminotrans- 
ferase levels (Fig. 2) improved significantly during 
the first 2 to 3 weeks, especially for patients with 
biventricular support. The LV apex was the favored 
cannulation site for inflow from the heart to the 
LVAD in all groups of patients. There was no 
difference in LVAD blood flow index in patients 
with univentricular or biventricular support, when 
comparing patients with left heart cannulation from 
either the LV apex or left atrium. The average 
duration of VAD support was 41 days (longest was 
247 days) for the LVAD group compared with 22 
days (longest was 236 days) for the BiVAD groups. 
Survival. The percentage of patients who sur- 
vived to receive a heart transplant (Table III) was 
significantly greater for the LVAD group (74%) 
than for the combined BiVAD groups (58%). How- 
ever, there was no significant difference between the 
groups in posttransplantation survival through hos- 
pital discharge. There were no statistically signifi- 
cant associations between patient survival and pre- 
operative mechanical ventilation, intraaortic balloon 
pumps, and emergency implants for either the 
LVAD or BiVAD groups. However, in the BiVAD 
group, patients without preoperative cardiac arrests 
had better survival-to-transplantation figures (66%) 
than those with preoperative cardiac arrests (47%, 
p = 0.03); cardiac arrest had no effect on survival in 
the LVAD group (74% vs 74%). For postoperative 
faetors, survival-to-transplantation in the BiVAD 
group was significantly better (67%) in patients who 
did not require dialysis than in those who did 
require dialysis (21%) (p = 0.000). However, patient 
survival was not significantly related to reoperations 
to control bleeding in either the BiVAD group 
(reoperation, 56% survival; no reoperation, 58% 
survival) or the LVAD group (reoperation, 60% 
survival; no reoperation, 77% survival). 
Discussion 
The principal results from this study indicate that 
patients receiving univentricular and biventrieular 
VADs as a bridge to cardiac transplantation are from 
different but overlapping patient populations. AI- 
though all patients were in imminent risk of dying 
before VAD support, patients who received isolated 
LVADs were less severely ill in the preoperative 
period and consequently had a lower mortality rate 
after the operation. As the severity of illness increased, 
patients were more likely to require biventricular 
support. The results of this smdy are consistent with 
the belief that the earlier the implantation, before 
significant major organ dysfunction, the more likely 
that univentricular support will be all that is required, 
and the greater the likelihood of survival through 
transplantation. 
In addition to more severe preoperative cardiac 
dysfunction, patients who received biventricular 
support had more severe pre-VAD renal, hepatic, 
and respiratory failure than did patients receiving an 
LVAD. Consistent with this preoperative clinical 
state, these patients had more frequent renal failure 
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and bleeding complications during VAD support. 
With the restoration of systemic blood flow, recov- 
ery of renal and hepatic function appeared to take 2 
to 4 weeks of VAD support in most patients, which 
is consistent with our previous report. 4 Although 
pre-VAD creatinine and total bilirubin levels were 
significantly greater in patients receiving biventricu- 
lar support, by the third week of support he levels in 
these patients were not significantly different from 
those in patients having an LVAD. 
One interesting finding is that hemodynamic mea- 
surements were not of rauch value in separating 
patients who required univentricular versus biven- 
tricular support. Pre-VAD cardiac indexes and pul- 
monary capillary wedge pressures were significantly 
lower in patients requiring BiVAD support, which is 
consistent with a greater severity of right heart 
failure, as is the nonsignificant increase in central 
venous pressure. However, the differences between 
group averages in these factors were only about 
10%. 
Once patients met the bridge-to-transplantation 
entry criteria in this study, investigators were free to 
choose univentricular or biventricular support. The 
results clearly reflect a wide range in severity of 
disease in patients studied and different philoso- 
phies of different surgical groups over a 10-year 
experience with this device. Many groups prefer to 
try to use isolated LVADs if possible and to add an 
RVAD only when required. This is a reasonable 
approach, because the extent of RV dysfunction 
sometimes becomes apparent only when the LVAD 
unmasks RV failure by attempting to increase ve- 
nous return to the right ventricle. However, because 
of the lack of reliable predictive risk factors and of 
the severe consequences if RV failure was present 
during isolated LVAD support, other groups use 
biventricular support in a large majority of patients. 
This approach simplifies medical management of
RV failure, pulmonary hypertension, or arrhythmias 
and obviates the need to implant an RVAD at a 
later time. 
Group 3 (the initial BiVAD group) represents he 
latter approach and probably contains patients who 
could have been successfully supported if only iso- 
lated LVADs had been used. However, there would 
be no a priori knowledge of which particular pa- 
ùtients those would be. In group 2 (converted BiVAD 
group), all patients (n = 37) had a demonstrated 
need for the addition of RVAD support, which 
represents 33% of those patients in whom isolated 
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Fig. 2. Preoperative creatinine (A) and total bilirubin (B) 
levels were greater in patients receiving BiVAD support 
than in those receiving LVAD support, but differences in 
aspartate aminotransaminase (AST) (C) did not reach 
significance. All values improved over several weeks of 
VAD support, and there was no difference between 
patients in the LVAD and BiVAD groups by 30 days. 
Values shown are mean _+ standard error of the mean. 
cient. No doubt, as improved selection criteria are 
developed, and as VADs are implanted earlier, it 
will become easier to predict which patients will 
require univentricular or biventricular support. 
The results from this study are in agreement with 
those of Kormos and associates, 8 who also con- 
cluded that the need for biventricular support is 
more dependent on the patient's clinical status than 
on hemodynamic parameters. There were no differ- 
ences in preimplantation hemodynamics in the Kor- 
mos study between patients who exhibited RV fail- 
ure during LV assist. Patients with biventricular failure 
during LV assist had significantly lower preoperative 
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mixed venous oxygen saturation, a greater level of 
inotropic need, impaired mental status, and a lower 
ratio of RV ejection fraction to inotropic need. 
Other factors that have been proposed as to when 
biventricular support might be strongly indicated 
include biventricular infarction, 11 potentially lethal 
arrhythmias, 12 low (<15%) RV ejection fraction 
and large RV volumes, 13 elevated fLxed pulmonary 
vascular esistance, and liver dysfunction. RV free 
wall ischemia, 14 septal ischemia, 15 and global car- 
diac ischemia 6 have also been proposed to be 
factors in RV failure when it is seen during LVAD 
support. Intraoperative bleeding and greater trans- 
fusion requirements of blood and blood products 
may also play a role in increasing pulmonary vascu- 
lar resistance and in the development of right heart 
failure, possibly requiring RVAD use. In this study 
postoperative bleeding requiring a reoperation was 
more prevalent in patients with biventricular de- 
vices, but it is not known how rauch this is related to 
the patient's preoperative status or to the procedure 
itself. 
In general, the criteria for predicting which pa- 
tients will require biventricular support are not well 
established. Clinical experience suggests that the 
earlier the implant, the better the chances of suc- 
ceeding with isolated LVAD support, which is con- 
sistent with the finding that the need for biventricu- 
lar support increases with severity of illness. Also, as 
new therapies become available, such as inhaled 
nitric oxide for pulmonary vasodilation, 17' 18 medical 
management of RV dysfunction may be improved 
but would have to be weighed against he known 
hemodynamic stability that can be achieved with 
biventricular support. 
The basic pathophysiologic principles of the in- 
teraction between the right and left ventricles as it 
pertains to RV function during LVAD support are 
reasonably well understood. 19Because of the close 
anatomic oupling between the right and left sides 
of the heart, the volume and pressure of one ven- 
tricle can affect the other ventricle, 2°-26 and an 
LVAD can have some effects on both hemodynamic 
interactions (e.g., increased RV venous return, re- 
duced pulmonary pressures) and anatomic mechan- 
ical interactions (e.g., leftward septal shift during 
LV unloading). Depending on pathophysiologic 
conditions, these effects can be either detrimental or 
beneficial to the determinants of RV function. 27' 28 
In normal animal models these effects tend to 
balance during left heart support, resulting in no 
overall change in RV performance. However, in 
human patients with LVADs as a bridge to cardiac 
transplantation, the dominant effect is beneficial: a 
reduction in RV afterload and an improvement in
RV function owing to relief from passive pulmonary 
hypertension during LVAD support.7, 8  19, 29, 30 
Therefore anatomic interactions between the ven- 
tricles appear to play a minor role in determining 
overall RV function during LVAD support com- 
pared with effects of preexisting or acquired patho- 
logic conditions. 
In conclusion, the results of this study indicate 
that patients are more likely to require biventricular 
support as the severity of illness increases. The 
earlier the implant he more likely the patient can be 
supported with a isolated LVAD and the greater the 
likelihood of survival through transplantation. How- 
ever, both groups of patients can be successfully 
supported, with posttransplantation survival compa- 
rable with that of conventional transplantation. 
We gratefully acknowledge the contributions of the 
principle investigators and support staff from all 35 hos- 
pitals that performed implants with the Thoratec VAD 
and collected the data used in this artMe. 
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